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Imoxin attenuates LPS‐induced inflammation and MuRF1 expression in
mouse skeletal muscle
Abstract
The double‐stranded RNA‐dependent protein kinase (PKR) contributes to inflammatory cytokine expression
and disease pathogenesis in many conditions. Limited data are available on the efficacy of the PKR inhibitor
imoxin to prevent lipopolysaccharide (LPS)‐induced inflammation in skeletal muscle in vivo. The aim of this
study was to evaluate the effect of imoxin, a PKR inhibitor, on inflammatory and atrophy signaling in skeletal
muscle in response to an acute inflammatory insult with LPS. Six‐week old C57BL/6J mice received vehicle
(saline) or 0.5 mg/kg imoxin 24 and 2 h prior to induction of inflammation via 1 mg/kg LPS. Gastrocnemius
muscles were collected 24 h post‐LPS and mRNA and protein expression were assessed. LPS lead to a loss of
body weight, which was similar in Imoxin+LPS. There were no differences in muscle weight among groups.
LPS increased gastrocnemius mRNA expression of TNF‐α and IL‐1β, and protein levels of NLRP3, all of
which were attenuated by imoxin. Similarly, IL‐6 mRNA and IL‐1β protein were suppressed in Imoxin+LPS
compared to LPS alone. LPS increased mRNA of the atrogenes, MuRF1 and MAFbx, and imoxin attenuated
the LPS‐induced increase in MuRF1 mRNA, and lowered MuRF1 protein. Imoxin+LPS increased p‐Akt
compared to saline or LPS, whereas p‐mTOR was unaltered. FoxO1 was upregulated and p‐FoxO1/FoxO1
reduced by LPS, both of which were prevented by imoxin. Both LPS and Imoxin+LPS had diminished
p‐FoxO3/FoxO3 compared to control. These results demonstrate the potential anti‐inflammatory and
anti‐atrophy effects of imoxin on skeletal muscle in vivo.
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Abstract
The double-stranded RNA-dependent protein kinase (PKR) contributes to
inflammatory cytokine expression and disease pathogenesis in many condi-
tions. Limited data are available on the efficacy of the PKR inhibitor imoxin to
prevent lipopolysaccharide (LPS)-induced inflammation in skeletal muscle
in vivo. The aim of this study was to evaluate the effect of imoxin, a PKR inhi-
bitor, on inflammatory and atrophy signaling in skeletal muscle in response to
an acute inflammatory insult with LPS. Six-week old C57BL/6J mice received
vehicle (saline) or 0.5 mg/kg imoxin 24 and 2 h prior to induction of inflam-
mation via 1 mg/kg LPS. Gastrocnemius muscles were collected 24 h post-LPS
and mRNA and protein expression were assessed. LPS lead to a loss of body
weight, which was similar in Imoxin+LPS. There were no differences in muscle
weight among groups. LPS increased gastrocnemius mRNA expression of TNF-
a and IL-1b, and protein levels of NLRP3, all of which were attenuated by
imoxin. Similarly, IL-6 mRNA and IL-1b protein were suppressed in Imox-
in+LPS compared to LPS alone. LPS increased mRNA of the atrogenes, MuRF1
and MAFbx, and imoxin attenuated the LPS-induced increase in MuRF1
mRNA, and lowered MuRF1 protein. Imoxin+LPS increased p-Akt compared
to saline or LPS, whereas p-mTOR was unaltered. FoxO1 was upregulated and
p-FoxO1/FoxO1 reduced by LPS, both of which were prevented by imoxin.
Both LPS and Imoxin+LPS had diminished p-FoxO3/FoxO3 compared to con-
trol. These results demonstrate the potential anti-inflammatory and anti-atro-
phy effects of imoxin on skeletal muscle in vivo.
Introduction
Skeletal muscle inflammation occurs in a variety of condi-
tions in which muscle loss is a complication (Costamagna
et al. 2015; Powers et al. 2016). A feature common in
many muscle wasting conditions is an elevation in circu-
lating endotoxin. High concentrations of endotoxin, or
lipopolysaccharide (LPS), have been observed in obesity,
insulin resistance, type 2 diabetes (Cani et al. 2008; Al-
Attas et al. 2009; Ghanim et al. 2009; Miller et al. 2009),
NAFLD (Harte et al. 2010), cancer (Han et al. 2007), and
chronic heart failure (Niebauer et al. 1999), likely
contributing to the muscle wasting observed in these con-
ditions. The administration of lipopolysaccharide (LPS) is
an established model that reproducibly induces skeletal
muscle inflammation (Frost et al. 2002; Lang et al. 2003;
Frost and Lang 2005; Huey et al. 2008a) and muscle atro-
phy gene expression (Dehoux et al. 2003). However, a full
understanding of the key players and events that coordi-
nate the complex catabolic signaling response to LPS is
still elusive.
The double-stranded RNA-dependent protein kinase
(PKR) contributes to inflammatory cytokine production
(Kang and Tang 2012) and metabolic dysregulation
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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(Nakamura et al. 2010). Indicators of PKR activity are
elevated in skeletal muscle in models of atrophy, includ-
ing cancer (Eley et al. 2008d) and diabetic conditions
(Russell et al. 2009; Carvalho et al. 2013). In in vitro,
stimulation with LPS, along with other atrophic agents,
increases PKR activity, resulting in activation of the ubiq-
uitin proteasome system (UPS) (Eley and Tisdale 2007;
Eley et al. 2008a,b,c, 2010; Supinski and Callahan 2011).
Additionally, PKR suppresses protein synthesis by phos-
phorylating, and inhibiting, eIF2a, a translational initia-
tion factor (Dey et al. 2005). Genetic inactivation of PKR
prevents the phosphorylation of eIF2a, resulting in
restoration of protein synthesis and suppression of pro-
tein degradation (Eley and Tisdale 2007; Eley et al. 2008a,
b; Supinski and Callahan 2011). Importantly, pharmaco-
logical inhibition of PKR with imoxin, also referred to as
compound 16 (C16), appears to recapitulate the genetic
effects, and has been shown to have anti-inflammatory
effects in multiple tissues (Supinski and Callahan 2011;
Tronel et al. 2014; Nakamura et al. 2015; Li et al. 2017).
However, in some instances, such as in response to viral
infection, PKR may be anti-inflammatory (Kapil et al.
2014). The role of PKR in inflammation appears to be
dependent on both context and cell type (Yoshida et al.
2012; Watanabe et al. 2018).
Whether PKR is involved in skeletal muscle inflamma-
tory and atrophy responses to LPS, in vivo, is not estab-
lished. Additionally, skeletal muscle signaling responses
that may be impacted by PKR in response to LPS have
not been fully characterized. In this context, the primary
objective of the current study was to evaluate the protec-
tive effect of imoxin, in vivo, against LPS-induced skeletal
muscle inflammation. We hypothesized that the PKR
inhibitor imoxin would alleviate the effects of LPS on
skeletal muscle inflammation and atrophy signaling.
Materials and Methods
Experimental design
Male C57BL/6J mice were purchased from Jackson Labo-
ratories (Bar Harbor, ME) at 5 weeks of age. Mice were
group housed on a 12:12-h light-dark cycle in a tempera-
ture-controlled (19–21°C) room at 4–5 mice per cage
with free access to water and standard chow. Mice were
acclimated for 1 week prior to experiments, then ran-
domly assigned to saline+saline (control), saline+LPS
(LPS), or Imoxin+LPS groups (n = 6–7 per group). Mice
received two subcutaneous (s.c.) injections of sterile saline
or 0.5 mg/kg imoxin (Calbiochem, San Diego, CA) given
24 and 2 h prior to an LPS challenge. Imoxin was recon-
stituted at 20 mmol/L in 100% EtOH (5.37 mg/mL), and
further diluted in saline to 0.1 mg/mL, and injected s.c.
(~0.1 mL/mouse). The dose of imoxin was selected based
on previous work demonstrating anti-inflammatory and
metabolic benefits with similar doses (Tronel et al. 2014;
Li et al. 2017), without noticeable ill effects, even with
prolonged use (Nakamura et al. 2014). Sterile saline or
LPS (serotype O111:B4, Sigma-Aldrich, St. Louis, MO)
was injected intraperitoneally (i.p.) at a dose of 1 mg/kg
in a 0.1 mg/mL saline solution, ~0.2 mL/mouse. The dose
of LPS was selected to induce skeletal muscle inflamma-
tion, without inducing sepsis, overt muscle atrophy, or
risk of mortality (Huey et al. 2008b; Li et al. 2015).
Twenty-four hours after LPS administration, mice were
euthanized by carbon dioxide inhalation, and gastrocne-
mius muscles were quickly removed, trimmed of excess
fat and connective tissue, wet weighed, and snap-frozen
in liquid nitrogen. Each gastrocnemius was processed for
both protein and mRNA, as described below. Protocols
for animal use were reviewed and approved by the Insti-
tutional Animal Care and Use Committee of Iowa State
University and were in accordance with the American
Physiological Society Animal Care Guidelines.
Chemicals and materials
Antibodies for NLRP3 (#13158), p-Akt (Ser 473) (#9721),
Akt (#9272), p-eIF2a (Ser 51) (#3398), p-FoxO1/p-FoxO3
(Thr 24/Thr 32) (#9464), p-mTOR (Ser 2448) (#2971),
mTOR (#2983), eIF2a (#5324), p-NF-jB (Ser 536) (#3033),
IjBa (#4814), and ubiquitin (#3933) were obtained from
Cell Signaling (Danvers, MA) and p-PKR (Thr 451)
(#44-668) was from Invitrogen (Carlsbad, CA). Mouse
monoclonal IL-1b (sc-1251), TNF-a (sc-52746), PKR
(sc-6282), MuRF1 (sc-398608), MAFbx (sc-166806), FoxO1
(sc-374427), FoxO3 (sc-48348), and NF-jB (sc-8008)
were from Santa Cruz Biotechnology (Santa Cruz, CA).
All other chemicals were purchased from Thermo Fisher
Scientific (Waltham, MA), unless otherwise indicated.
mRNA analysis
Gastroc samples (~50 mg) were homogenized in 1 mL
TRIzol. Total RNA was extracted and concentration was
quantified spectrophotometrically using the NanoDrop
system (NanoDrop Technologies, Wilmington, DE). Total
RNA (1 lg) was reverse transcribed to cDNA using a
Verso cDNA Synthesis Kit (Thermo Scientific, Grand
Island, NY) according to manufacturer instructions.
Quantitative real-time PCR was performed with 20 ng/re-
action using iTaq Universal SYBR Green Supermix (Bio-
Rad, Hercules, CA), and run on a MyiQ PCR system
(Bio-Rad, Hercules, CA). Each gene was normalized
against the housekeeping gene GAPDH, using the DDCT
method, and mRNA expression for each gene is presented
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as mean fold-change relative to the saline (control) mice.
The primer sequences used for each gene are as follows:
GAPDH forward: CCAGCTACTCGCGGCTTTA, reverse:
GAGGGCTGCAGTCCGTATTT; TNF-a: forward: AGCC-
GATGGGTTGTACCTTG, reverse: ATAGCAAATCGGCT-
GACGGT; IL-6: forward: TCCAGTTGCCTTCTTGGGAC,
reverse: AGTCTCCTCTCCGGACTTGT; IL-1b: forward:
TGCCACCTTTTGACAGTGATG, reverse: TGATGTGCT
GCTGCGAGATT; NLRP3: forward: GACACGAGTCCTG
GTGACTTT, reverse: CAGACGTATGTCCTGAGCCAT;
MuRF1: forward: TGTCTCACGTGTGAGGTGCCTA, reverse:
CACCAGCATGGAGATGCAGTTAC; MAFbx: forward: AC
ATTCTGCCAGCTGCTGTTTC, reverse: TGAGTTGGATG
CTGGGCCTAC.
Protein analysis
Frozen gastrocnemius samples (40–50 mg) were homoge-
nized in 109 volume of ice-cold buffer containing
30 mmol/L NaHepes (pH 7.4), 5 mmol/L EGTA,
3 mmol/L EDTA, 32% glycerol, 20 mmol/L KCl, HALT
protease inhibitor cocktail (Thermo Fisher, Waltham,
MA) and phosphate inhibitor cocktail 3 (Sigma-Aldrich,
St. Louis, MO). Tissue homogenates were centrifuged at
12,000g for 15 min at 4°C, and supernatants were col-
lected. Protein concentration was assessed by the bicin-
choninic acid method (BCA; Pierce Biotechnology, Inc.,
Rockford, IL), with BSA for the standard curve.
Western blot analysis
Protein homogenates (15–30 lg) were run on a 4–15%
gradient Stain-Free Criterion TGX gel (Bio-Rad, Her-
cules, CA), and transferred onto a PVDF (polyvinylidene
difluoride) membrane (EMD Millipore, Burlington, MA).
Gels were activated according to Bio-Rad’s Stain-Free
protocol, and membranes were imaged to ensure even
transfer and quantify total protein, as recommended
(Ghosh et al. 2014), then blocked in Tris-buffered saline
(pH 7.5) containing 0.05% Tween-20 (TBST) and 5%
non-fat dry milk for 1 h at room temperature. Next, they
were incubated overnight in primary antibodies at a
1:1000 dilution. They were then washed with TBST, incu-
bated with a secondary antibody conjugated to horserad-
ish peroxidase (Cell Signaling) at a 1:5000 dilution, and
subjected to an enhanced chemiluminescence solution.
Western blot images were captured with the ChemiDocTM
XRS Imaging System (Bio-Rad, Hercules, CA), and den-
sitometry was performed using Image Lab V6.0 (Bio-Rad,
Hercules, CA).
Statistics
Statistical differences between groups were determined by
one-way analysis of variance (ANOVA) with a Newman–
Keuls post-hoc test (Graphpad Prism; V6.01; GraphPad
Software, Inc., CA). Data are reported as mean  SEM
and considered significant at P < 0.05.
Results
Body and muscle weight
Initial body weights were less in the Imoxin+LPS mice
compared to LPS mice (P < 0.05), but did not differ
across remaining groups (Table 1). As expected, mice lost
body weight (2.7  0.5 g), following LPS injection,
which was not affected by imoxin pretreatment
(2.3  0.7 g). In accordance with previous reports,
absolute and relative gastrocnemius and soleus muscle
weights were not affected by this dose of LPS (Huey et al.
2008b). To rule out an effect of imoxin alone on body
weight and muscle weight, a subset of mice received twice
the dose of imoxin (1.0 mg/kg), and weights were not
altered (Table 1).
Muscle inflammatory mRNA and protein
expression
LPS increased the mRNA expression of TNF-a and IL-1b,
by 2.4-fold and 12.8-fold, respectively, compared to sal-
ine-treated mice. Pretreatment with imoxin attenuated
Table 1. Body and muscle weight.
Control
Imoxin
1 mg/kg LPS
Imoxin
0.5 mg/kg + LPS
Body weight (pretreatment) 23.2  0.6 22.3  0.7 24.1  0.6 21.8  0.4#
Body weight change (%) 0.5  0.5 2.1  0.2 -11.3  0.8*† -10.2  0.7*†
Gastrocnemius weight (mg) 140.6  5.9 129.0  6.1 130.7  6.5 124.3  3.0
Relative gastrocnemius weight (mg/g BW) 6.0  0.2 5.7  0.2 6.1  0.2 6.4  0.1
Body weight and weight loss 24 h after 1 mg/kg LPS injection. Weight of gastrocnemius muscles are averages of left and right limbs. Values
are mean  SE, n = 5–7 per group. *P < 0.05 compared to control, #P < 0.05 compared to LPS, †P < 0.05 compared to Imoxin 1 mg/kg.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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the LPS-induced increases in both, by 46% and 66%,
respectively (P < 0.05; Fig. 1A). Although LPS did not
significantly increase IL-6 mRNA expression, levels were
63% lower in Imoxin+LPS compared to LPS alone
(P < 0.05). There were no differences among groups on
NLRP3 gene expression (ANOVA P = 0.26).
There was no change in TNF-a protein across treat-
ments (ANOVA P = 0.3). At the protein level, LPS signif-
icantly increased NLRP3 (6.4-fold) compared to the saline
control. Although elevated compared to saline-treated
mice (3.9-fold), mice receiving imoxin had significantly
lower (39%) NRLP3 levels than LPS alone (Fig. 1B).
There was no LPS effect on IL-1b; however, both pro-
and mature IL-1b were significantly lower in Imoxin+LPS
then control and LPS (Fig. 1B). There was a tendency for
a difference across groups in p-PKR and total PKR
(ANOVA P = 0.07 for both), with LPS increasing each by
111% and 99%, respectively (Fig. 2). Compared to LPS,
p-PKR and total PKR were reduced by 48% and 33%,
respectively, by Imoxin+LPS, although these were not
significantly different (Fig. 2). There was no effect of
treatments on p-eIF2a or total eIF2a.
Muscle atrophy-related gene and protein
expression
LPS is an established model to induce atrophic signaling
through upregulating the transcription of the muscle
enriched ubiquitin ligases MAFbx (atrogin-1) and MuRF1
(Doyle et al. 2011). As expected, LPS increased MuRF1
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Figure 1. Inhibition of PKR with imoxin attenuates LPS-induced skeletal muscle inflammation. Male C57BL/6J mice were injected s.c. with
0.5 mg/kg imoxin or saline 2 h and 24 h prior to 1 mg/kg LPS administered i.p. Gastrocnemius muscles were harvested 24 h following saline
or LPS. Gene expression of inflammatory cytokines was determined by qPCR (A). Inflammatory proteins were assessed via western blot and
representative blots and quantification are displayed (B). Data are expressed relative to saline control mice, and presented as mean  SE
(n = 6–7/group). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the Control group, #P < 0.05, ##P < 0.01, and ###P < 0.001
compared with the LPS group.
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mRNA compared to control (23-fold), which was attenu-
ated by >50% in Imoxin+LPS (Fig. 3A). Similarly, LPS
increased MAFbx gene expression (14-fold); however,
imoxin did not affect this increase. MuRF1 protein was
not increased in response to LPS; however, it was signifi-
cantly lower, by 18% and 22%, in Imoxin+LPS compared
to control and LPS, respectively (Fig. 3B). Protein levels
of MAFbx increased ~4-fold, in both LPS and Imox-
in+LPS compared to control.
Neither LPS nor Imoxin+LPS had an effect on phos-
phorylation of the anabolic molecule mTOR. Although
LPS alone had no effect on Akt phosphorylation, Imox-
in+LPS had significantly greater p-Akt compared to both
control and LPS mice (Fig. 4A). There were no treatment
effects on p-FoxO1. Total FoxO1 was upregulated by 33%
in response to LPS (P < 0.05), but this response was
completely prevented in Imoxin+LPS. The ratio of
p-FoxO1/FoxO1 was reduced by LPS, and this was pre-
vented in Imoxin+LPS (Fig. 4B). Total FoxO3 did not
differ across groups. Phospho-FoxO3 was lower in Imox-
in+LPS compared to control, whereas the p-FoxO3/
FoxO3 ratio was lower in both LPS and Imoxin+LPS,
with no difference between the two (Fig. 4B). Despite
changes in atrogenes and FoxO signaling, protein ubiqui-
tination only tended to differ across groups (ANOVA
P = 0.08; Fig. 4C), elevated by 16% and 21% in LPS and
Imoxin+LPS, respectively. No treatment effects on phos-
phorylated or total NF-jB were observed (Fig. 5). IjB
protein expression was increased by LPS, but was not ele-
vated in Imoxin+LPS.
Discussion
The adverse effects of PKR on whole body (Nakamura
et al. 2010) and muscle metabolism (Eley et al. 2010)
have been described. Many of the deleterious conse-
quences of PKR activity have been attributed to its
involvement in inflammatory signaling (Kang and Tang
2012). The PKR inhibitor, imoxin, has anti-inflammatory
effects in the lung, liver, and central nervous system (Tro-
nel et al. 2014; Nakamura et al. 2015; Li et al. 2017), and
has benefits on metabolic health (Nakamura et al. 2014).
We show here that this finding extends to skeletal muscle,
as expression of several inflammatory cytokines induced
by LPS, including TNF-a, IL-1b, and NLRP3, were atten-
uated by pretreatment with imoxin.
Interestingly, PKR appears to regulate NLRP3 inflam-
masome activity, including maturation and secretion of
IL-1b (Lu et al. 2012). However, others have suggested
that PKR activity, while essential for some cytokines fol-
lowing LPS stimulation, does not modulate the inflamma-
some (He et al. 2013; Hett et al. 2013). Elevated NLRP3
has an established role in insulin resistance (Vandan-
magsar et al. 2011; Wen et al. 2011) and may compro-
mise muscle function (Boursereau et al. 2018). It was
recently shown that NLRP3 knock-out mice are protected
from sepsis-induced muscle inflammation, atrophy
(Huang et al. 2017), and sarcopenia (McBride et al.
2017). To our knowledge, no previous studies have
related PKR and NLRP3 in skeletal muscle. Similarly, lim-
ited evidence exists regarding the role of imoxin, in vivo,
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representative images and quantification are shown. Values are presented as mean  SE (n = 6–7/group).
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on the skeletal muscle response to an inflammatory insult.
We observed a significant increase in muscle NLRP3 pro-
tein upon LPS stimulation, which was attenuated in
Imoxin+LPS, supporting a potential role of PKR in
inflammasome signaling. Similarly, although neither pro
nor mature IL-1b was increased by LPS, both were lower
in Imoxin+LPS,
Pro-inflammatory cytokines, including IL-1b, IL-6, and
TNF-a, induce expression the atrogenes MuRF1 and
MAFbx, and lead to muscle atrophy (Lang et al. 2002;
Frost and Lang 2005; Haddad et al. 2005; Huang et al.
2017). Given our observations that imoxin attenuated
inflammation and NLRP3 signaling, we investigated the
effect of imoxin on LPS-induced expression of these
genes. As expected, both MAFbx and MuRF1 mRNA were
robustly increased by 23-fold and 14-fold, respectively, in
the group that received LPS alone compared to control
(Dehoux et al. 2003). Importantly, pretreatment with
imoxin attenuated the increase in MuRF1 compared to
LPS alone by approximately ~50%, but had no effect on
MAFbx. The observed reduction in MuRF1 could have
important implications for blunting muscle atrophy.
Although accelerated muscle protein breakdown plays
the dominant role in muscle wasting induced by inflam-
mation, LPS may also impair anabolic signaling and sup-
press protein synthesis (Vary 1998; Eley and Tisdale 2007;
Eley et al. 2008a). Akt has a well-established role in ana-
bolic signaling, but also opposes protein degradation
(Bodine et al. 2001) by suppressing the expression of
atrogenes through inhibition of FoxO activity (Stitt et al.
2004). Reductions in phosphorylation status of FoxO
(e.g., FoxO1 and FoxO3) by LPS induces nuclear translo-
cation and transcriptional activity, resulting in elevations
in MAFbx and MuRF1 (Bodine and Baehr 2014). Inacti-
vation of FoxO can induce hypertrophy and attenuate
MuRF1 and MAFbx under septic conditions (Reed et al.
2012). In the current study, Akt phosphorylation, an indi-
cator of Akt activity, was elevated in Imoxin+LPS mice
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Figure 3. Imoxin attenuates LPS-induced expression of MuRF1, but not MAFbx in skeletal muscle. Atrogene mRNA (A) and protein (B)
expression were quantified from gastrocnemius muscle 24 h following LPS injection or saline (Con). Imoxin was administered (0.5 mg/kg, s.c.) 2
and 24 h prior to LPS (Imoxin+LPS). Data are expressed relative to control mice, and presented as mean  SE (n = 6–7/group). *P < 0.05 and
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compared to LPS alone. While we did not observe a
change in p-FoxO1, the ratio of p/total FoxO1 was
reduced by LPS, but unchanged in Imoxin+LPS. This
could suggest a potential reduction in LPS-induced
FoxO1 nuclear translocation and transcriptional activity
by imoxin, but cannot be determined in the current
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study. This finding could potentially explain the blunted
MuRF1 observed with Imoxin+LPS, but does not explain
the discordant findings between MuRF1 and MAFbx.
The transcription factor NF-jB is induced by inflam-
mation, and results in elevated transcription of MuRF1
and a muscle wasting phenotype, without affecting
MAFbx (Cai et al. 2004). As such, we assessed whether
differences in NF-jB could have accounted for the
blunted MuRF1 expression in Imoxin+LPS that was not
observed for MAFbx, but observed no differences in NF-
jB across treatments. Typically, under inflammatory stim-
uli, IjBa is degraded, allowing NF-jB to translocate to
the nucleus and induce transcription. With prolonged
stimulation, such as the 24 h timepoint assessed here,
NF-jB also induces transcription of IjB, providing nega-
tive feedback to suppress NF-jB (Scott et al. 1993; Hoff-
mann et al. 2002). Here, we observed an elevation in
IjBa in LPS that was absent in Imoxin+LPS. The role of
NF-jB on the anti-catabolic effects of imoxin remains
unclear.
Our data are in line with previous reports demonstrat-
ing that compounds that induce atrophy, including LPS,
consistently increase p-PKR and reduce protein synthesis
in vitro. Use of a catalytically inactive PKR variant and
pharmacological inhibition of PKR with imoxin prevent
protein degradation and restore protein synthesis dis-
rupted by these various atrophic or inflammatory stimuli
(Eley and Tisdale 2007; Eley et al. 2008a,b; Russell et al.
2009; Supinski and Callahan 2011), whereas imoxin alone
does not affect protein synthesis (Eley and Tisdale 2007).
Similarly, PKR inhibition in vivo has been shown to pro-
tect against diaphragm dysfunction (Supinski and Calla-
han 2011) and cancer cachexia (Eley et al. 2007).
We observed elevated expression of TNF-a and IL-1b
whereas others have shown this to be resolved by 24 h
(Huey et al. 2008a,b). Our data corroborate that IL-6
mRNA changes more transiently, returning to baseline
levels within 24 h (Huey et al. 2008a), although imoxin-
treated mice had lower IL-6 than LPS alone. Despite
observed elevations, cytokine expression typically peaks
early, within 4 h, after LPS exposure (Lang et al. 2003),
and precedes increases in MuRF1 and MAFbx mRNA
(Murton et al. 2009). Similarly, we did not observe a sig-
nificant increase in p-PKR or p-eIF2a 24 h after LPS.
Others have reported an earlier peak in p-PKR following
LPS administration, occurring between 4 and 8 h, then
returning to baseline (Supinski and Callahan 2011; Li
et al. 2017). Our study is limited to this single 24 h time-
point. The reported timecourse of PKR phosphorylation
suggests that activity of PKR is transient following a sin-
gle inflammatory insult, and that PKR activation precedes
other inflammatory changes, which remained elevated at
24 h. However, the possibility exists that imoxin may be
working through off-target mechanisms. For example,
imoxin has been shown to inhibit CDK activity in
neurons, eliciting therapeutic effects independent of PKR
signaling (Chen et al. 2008). Imoxin may also exert anti-
inflammatory effects by blunting TLR4 signaling. In the
absence of TLR4, macrophages stimulated with LPS had
>50% reduction in PKR, and an absence of LPS-induced
p-PKR (Li et al. 2015).
In the current study, we did not assess contractile
function, as this was not expected to decline with this
dose of LPS (Meador and Huey 2009). In addition, we
have not determined whether skeletal muscle per se, or
resident immune cells are targeted by imoxin, leading to
the observed decrease in LPS-induced inflammation. Fur-
thermore, our single inflammatory insult did not cause
overt loss of muscle or muscle atrophy or significantly
elevate protein ubiquitination. Regardless, there appears
to be less skeletal muscle inflammation and MuRF1
mRNA in mice receiving imoxin prior to LPS. This find-
ing suggests that imoxin administration may protect
skeletal muscle and possibly preserve muscle function,
under inflammatory conditions; however, the efficacy of
imoxin as a treatment following an inflammatory insult
warrants further investigation. Longer-term studies
should be conducted to determine the therapeutic poten-
tial of chronic PKR inhibition with imoxin on the
preservation of skeletal muscle health. Notably, prolonged
daily administration of imoxin, at the dose used in this
study, improved metabolic health in a mouse model of
diabetes, with no observed ill effects (Nakamura et al.
2014).
Conclusion
Results of the current study provide evidence that short-
term administration of the PKR inhibitor imoxin attenu-
ates skeletal muscle inflammation and NLRP3 in vivo, in
response to a subsequent acute inflammatory insult with
LPS. Furthermore, imoxin blunted the LPS-induced
reduction in FoxO1 phosphorylation and increase in
mRNA of the atrogene MuRF1. These findings highlight
the potential of imoxin to protect against skeletal muscle
inflammation and preservation of muscle mass and func-
tion, which require further study.
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